AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03331263
Drug: Chlorhexidine Gluconate
RxNorm normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2% CHG
Trial: NCT00818155
Drug: desvenlafaxine succinate SR
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: desvenlafaxine succinate SR
Trial: NCT01003379
Drug: TC-5619
RxNorm normalized name: TC-6987
DrugBank: TC-6987 (DB14854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TC-5619-238 will be provided as hard gelatin capsules in strengths of 1mg, 5mg, and 25mg.
Trial: NCT03836157
Drug: Mirvetuximab Soravtansine
RxNorm normalized name: MIRVETUXIMAB SORAVTANSINE
DrugBank: Mirvetuximab soravtansine (DB12489)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose will not be recalculated unless the patient has ±10% weight change.
Trial: NCT03836157
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subject will receive IMGN853 first followed by bevacizumab. There is no planned delay between the IMGN853 and bevacizumab administration.
Trial: NCT00091468
Drug: Transdermal nicotine patch
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: double-blind phase: 5mg for 1 week, 10mg for 2 weeks, 15mg for 23 weeks open label phase: 5mg for 1 week, 10mg. for 2 weeks, 15mg. for 23 weeks taper down: 10mg. for 2 weeks, 5mg. for 1 week
Trial: NCT00780780
Drug: triamcinolone intravitreal injection
RxNorm normalized name: triamcinolone Injection
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: triamcinolone intravitreal injection
Trial: NCT00652145
Drug: mesalamine
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increase dose by 2.4gm per day over baseline dose
Trial: NCT02750332
Drug: Nitisinone
RxNorm normalized name: Nitisinone
DrugBank: Nitisinone (DB00348)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single oral dose of Nitisinone 10 mg Tablet will be administered.
Trial: NCT04566718
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: metformin cessation
Trial: NCT01757860
Drug: CARD-024
RxNorm normalized name: danicopan
DrugBank: Danicopan (DB15401)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of different dosages of drug
Trial: NCT01473940
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02608996
Drug: Nesiritide
RxNorm normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This intervention is designed to determine the optimal dose range of BNP for treatment of patients with uncontrolled hypertension
Trial: NCT03319316
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Combination of durvalumab + tremelimumab treatment
Trial: NCT00841945
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: RITUXIMAB 375 MG/M² IV DAY 1 or each course
Trial: NCT03319316
Drug: Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of durvalumab + tremelimumab treatment
Trial: NCT01534117
Drug: DDAVP
RxNorm normalized name: DDAVP
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Desmopressin 0.3mcg/kg IV x 1
Trial: NCT00841945
Drug: vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VINCRISTINE 1?4 MG/M² IV ON DAY 1
Trial: NCT00841945
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone 40 mg/m² DAy 1 to day 5
Trial: NCT01706835
Drug: aldoxorubicin
RxNorm normalized name: Aldoxorubicin
DrugBank: Aldoxorubicin (DB06013)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03283046
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose Escalation Phase Starting Dose: Nivolumab 1 mg/kg by vein over 60 minutes every 3 weeks for 4 doses, followed by Nivolumab 240 mg by vein every 2 weeks until disease progression or unacceptable toxicity on Days 1 and 15 each cycle.~Dose Expansion Phase Starting Dose: Maximum tolerated dose (MTD) from Dose Escalation Phase.~Maintenance: Nivolumab 240 mg by vein every 2 weeks until disease progression or unacceptable toxicity on Days 1 and 15 each cycle.
Trial: NCT00249847
Drug: Paroxetine controlled-release
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2-12.5 mg tablets, orally, every day for 4 weeks
Trial: NCT00249847
Drug: Conjugated equine estrogen
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.625 mg tablet, orally, every day for 4 weeks
Trial: NCT03199170
Drug: Intrathecal morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5% Hyperbaric bupivacaine 2 ml add morphine 0.2 mg for spinal anesthesia
Trial: NCT03199170
Drug: Bilateral Quadratus Lumborum Block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% Bupivacaine 25 ml each side for quadratus lumborum block without spinal morphine
Trial: NCT03283046
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose Escalation and Dose Expansion Dose: Lenalidomide 25 mg by mouth on Days 1- 14 in 21 day cycles and Days 1-21 in 28 day cycles.~Maintenance: Lenalidomide 10 mg by mouth on Days 1-21.
Trial: NCT03283046
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose Escalation and Dose Expansion Dose: Dexamethasone 40 mg by mouth on Days 1,8,15 in 21 day cycles and 1,8,15 and 22 in 28 day cycles
Trial: NCT03199170
Drug: Intrathecal morphine with bilateral Quadratus Lumborum Block
RxNorm normalized name: Ivy Block
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5% Hyperbaric bupivacaine 2 ml add morphine 0.2 mg for spinal anesthesia and 0.25% Bupivacaine 25 ml each side for quadratus lumborum block
Trial: NCT03283046
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose Escalation and Dose Expansion Dose: Ipilimumab 1 mg/kg by vein over 90 minutes every 3 weeks for 4 doses.~Maintenance: If there is evidence of disease progression, Ipilimumab reintroduced at 3 mg/kg every 3 weeks for 4 doses. (Nivolumab dose in Combination determined by the phase 1 portion).
Trial: NCT03924596
Drug: Potassium Sodium Hydrogen Citrate
RxNorm normalized name: sodium hydrogen sulfite
DrugBank: Potassium sodium hydrogen citrate (DB16585)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uralyt-U (Potassium Sodium Hydrogen Citrate, 10g orally in 3 divided doses with pH target 6.2-6.8 for Calcium Oxalate stones and 7.0-7.2 for Uric Acid stones)
Trial: NCT03568708
Drug: Transdermal Estrogen
RxNorm normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In an open-label fashion, participants with POI will receive transdermal estradiol (beginning at a dose of 25 µg/patch applied weekly), with the dose increased at 3, 6 12, and 18 months (to 37.5, 50, 75, and 100 µg/patch).
Trial: NCT04498702
Drug: APL-1202 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A modified 3+3 design was employed: The dose was started at 300 mg and increased to 450 mg, 600 mg and 750 mg if there was no dose-limiting toxicity (DLT) in 3 subjects after 4-week consecutive administration of APL-1202. When the dose-escalation study was in progress, the doses for any newly enrolled subjects would be the starting dose or the highest dose confirmed with no DLT by the dose-escalation cohort at the time of enrollment. When the MTD or the 750 mg daily dose was attained as a safe dose, the dose for all subjects in the study or subsequently enrolled subjects would be MTD or 750 mg/day.
Trial: NCT01870999
Drug: aripiprazole IM depot
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole IM depot supplied as 200 mg or 400 mg vials of lyophilized aripiprazole powder to prepare for IM injection.
Trial: NCT02853526
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol is a kind of non-selective beta blockers, and is used for reducing the portal pressure.
Trial: NCT02853526
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral warfarin was used for six months to one year prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal.
Trial: NCT00812175
Drug: Sorafenib (Nexavar, BAY43-9006)
RxNorm normalized name: sorafenib 200 MG [Nexavar]
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic oral therapy according to product information
Trial: NCT03176121
Drug: Oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will take either CR oxycodone or IR oxycodone or both for initial dose and used it to titrate his/her background dose.
Trial: NCT01870999
Drug: aripiprazole tablets
RxNorm normalized name: Aripiprazole Tablets
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole tablets 10 mg once daily in the morning for 14 days.
Trial: NCT01401946
Drug: soy isoflavones
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00635921
Drug: ziprasidone
RxNorm normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose flexible from 40 to 200 mg/d during 12 weeks
Trial: NCT02609386
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Method of Administration: Omeprazole is administered orally for 21 days
Trial: NCT00626652
Drug: K201 Injection
RxNorm normalized name: K201 free base
DrugBank: K201 free base (DB02929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single intravenous infusion of Dose 1 - 10 or placebo (saline) or single oral capsule Dose A or placebo capsule
Trial: NCT03557918
Drug: Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab 750 mg IV on Day 1 of each 28 day cycle; up to 7 cycles.~Subjects that complete all initial 7 cycles but later progress during follow up may receive an additional 7 cycles of tremelimumab providing they meet eligibility criteria.
Trial: NCT03711305
Drug: SHR-1316
RxNorm normalized name: Immunoglobulin G4 (52-glycine, 57-phenylalanine, 227-proline, 233-alanine, 234-alanine, 446-alanine), anti-(human programmed death-ligand 1) (human-mus musculus monoclonal SHR-1316 .gamma.4-chain) fusion protein with peptide linker ((ggggs)4g) fusion protein with 20-136-type II transforming growth factor .beta. receptor (human isoform 1), disulfide with (85-glutamic acid) human-mus musculus monoclonal SHR-1316 .kappa.-chain, dimer
DrugBank: Retlirafusp alfa (DB17517)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1316 intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6) and maintenance phase.
Trial: NCT00940914
Drug: ioflupane 123I (DATSCAN®)
RxNorm normalized name: Ioflupane (123I)
DrugBank: Ioflupane I-123 (DB08824)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One administration (2,5 ml) of ioflupane 123I 0,07-0,13 µg/ml; 74 MBq/ml; IV (in the vein)
Trial: NCT03711305
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
Trial: NCT03711305
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
Trial: NCT00809536
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 225 mg q12, oral PD 0332334 immediate release formulation on Days 1 through 5; Single, oral, 500 mg dose of metformin immediate release
Trial: NCT00809536
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single, oral, 500 mg of metformin immediate release
Trial: NCT00809536
Drug: PD 0332334
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg q12, oral metformin immediate release administered on Days 1 through Day 6 Single, oral, 300 mg dose of PD 0332334 immediate release formulation administered on Day 3
Trial: NCT00809536
Drug: PD 0332334
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single, oral, 300 mg dose of PD 0332334 immediate release formulation
Trial: NCT00148499
Drug: Ambroxol hydrochloride (Mucoangin?)
RxNorm normalized name: ambroxol
DrugBank: Ambroxol (DB06742)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03942861
Drug: Solu-Medrol
RxNorm normalized name: SOLU-Medrol
DrugBank: Methylprednisolone hemisuccinate (DB14644)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment according to Danish Guidelines for acute severe ulcerative colitis.
Trial: NCT00459771
Drug: AT1 blocker candesartan
DrugBank: Candesartan (DB13919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT1 blocker candesartan, 32 mg oral QD
Trial: NCT00555334
Drug: lamivudine or entecavir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lamivudine (100mg qd) or entecavir (0.5mg qd) after RFA
Trial: NCT00006029
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00006029
Drug: vinorelbine tartrate
RxNorm normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04391179
Drug: Dipyridamole 100 Milligram(mg)
RxNorm normalized name: dipyridamole 100 MG
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug will be given for 14 days while in the hospital.
Trial: NCT00884260
Drug: Levonorgestrel IUS (LCS, BAY86-5028)
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In Vitro release rate: 12µg LNG/24h
Trial: NCT02095197
Drug: Triamcinolone 80mg
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: C7-T1 Cervical interlaminar epidural steroid injection with Triamcinolone 80mg and 1 mL 1% lidocaine. Total volume is 2 cc.
Trial: NCT02535650
Drug: tipifarnib
RxNorm normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tipifarnib will be administered at a starting dose of 900 mg, po, bid on days 1-7 and 15-21 of 28-day treatment cycles. In the absence of unmanageable toxicities, subjects may continue to receive tipifarnib treatment for up to 12 months as long as the Investigator considers that the treatment is providing clinical benefit.
Trial: NCT00716807
Drug: nalbuphine plus naloxone
DrugBank: Nalbuphine (DB00844)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient group: temporomandibular disorders. Nalbuphine 5 mg administered by nasal spray (one time only). Naloxone 0.4 mg administered by nasal spray (one time only).
Trial: NCT00716807
Drug: nalbuphine plus placebo
DrugBank: Nalbuphine (DB00844)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient group: temporomandibular disorders. Nalbuphine 5 mg administered by nasal spray (one time only). Placebo (naloxone vehicle) administered by nasal spray (one time only).
Trial: NCT01831427
Drug: Andecaliximab
RxNorm normalized name: Andecaliximab
DrugBank: Andecaliximab (DB17564)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Andecaliximab administered by intravenous (IV) infusion or subcutaneous (SC) injection
Trial: NCT04033406
Drug: VIR-2482
RxNorm normalized name: tick-borne encephalitis purified antigen
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIR-2482 given by intramuscular injection
Trial: NCT01027468
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intraocular bevacizumab injection
Trial: NCT03442088
Drug: Apremilast
RxNorm normalized name: Apremilast
DrugBank: Apremilast (DB05676)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Apremilast will be given as approved by the FDA for the treatment of moderate to severe plaque psoriasis. An initial dosage titration from Day 1 (10mg) to Day 5 (30mg). Following the titration, the recommended maintenance dosage of 30 mg twice daily taken orally starting on Day 6 will be dispensed, as per labeled indication.
Trial: NCT04221360
Drug: CKD-375
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug, QD, PO
Trial: NCT04221360
Drug: D390
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Reference drug, QD, PO
Trial: NCT00536510
Drug: laropiprant/niacin (MK0524A)
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Period 1: one 20mg/1g tablet laropiprant/niacin once daily for 4 weeks~Treatment Period 2: two 20mg/1g tablets laropiprant/niacin once daily for 8 weeks.~All patients will receive placebo for a 4 week run-in period before randomization
Trial: NCT00209950
Drug: Gaboxadol
RxNorm normalized name: Gaboxadol
DrugBank: Gaboxadol (DB06554)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02311608
Drug: Terlipressin
RxNorm normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered as a first-line medicine or as salvage
Trial: NCT02311608
Drug: Usual Dose Somatostatin/Octreotide
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: administered as a first-line medicine or as salvage
Trial: NCT02311608
Drug: High Dose Somatostatin/Octreotide
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: administered as salvage
Trial: NCT00968955
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local infiltration with ropivacaine 0,2% (150 ML)
Trial: NCT00699023
Drug: ezetimibe tablets
RxNorm normalized name: Ezetimibe Tablets
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ezetimibe tablets 10 mg/die
Trial: NCT00028262
Drug: Cystagon
RxNorm normalized name: Cystagon
DrugBank: Cysteamine (DB00847)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01979523
Drug: Trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01979523
Drug: Uprosertib
RxNorm normalized name: Uprosertib
DrugBank: Uprosertib (DB11969)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06392152
Drug: Focal Mass Drug Administration with Primaquine
DrugBank: Primaquine (DB01087)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A population census was conducted in each village in August 2019 to record the demographic information and malaria histories of the villagers. Vulnerable groups such as pregnant women, breastfeeding mothers, and children under 7 years were excluded from PQ administration.~Both Group 1 \&2 underwent a preliminary clinical assessment to exclude individuals with G6PD deficiency and low hemoglobin levels.~Based on the WHO malaria treatment guidelines, a standard PQ regimen of 0.25 mg PQ base/kg body weight daily for 14 days was administered through directly observed treatment (DOT) to ensure drug intake and monitor potential adverse effects. The safety of each participant was monitored by follow-up blood testing using Hemocue's hemoglobin photometers to track changes in hemoglobin levels.~As per cross-over design, eligible individulas from Group-1 received PQ-MDA in year 1 and Group-2 received PR-MDA in the following year.
Trial: NCT00459719
Drug: Tacrolimus modified-release
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00459719
Drug: Prograf
RxNorm normalized name: Prograf
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01135524
Drug: Buprenorphine transdermal patch
RxNorm normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine transdermal patch 5 mcg/h applied transdermally for 7-day wear.
Trial: NCT01135524
Drug: Buprenorphine transdermal patch
RxNorm normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine transdermal patch 10 mcg/h applied transdermally for 7-day wear.
Trial: NCT01135524
Drug: Buprenorphine transdermal patch
RxNorm normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine transdermal patch 20 mcg/h applied transdermally for 7-day wear.